U UNIQURE NV
| Market Cap | $1.07B |
| P/E Ratio | — |
| Forward P/E | -6.35 |
| Dividend Yield | — |
| Beta | 0.75 |
| 52W Range | $8.34 - $70.59 |
| # Hedge Funds | 1 |
| Sector | Healthcare |
| Industry | Biotechnology |
Hedge Fund Ownership
| Investor 1 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Lee Ainslie Maverick Capital | 0.17% | $15.84M | 661,820 | Buy |
Insider Trading
| Insider Name of the company insider who made the trade 26 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Kapusta Matthew CCEO, Managing Director | Sale | 14,581 | $9.06 | $132.10K | 04 Mar 2026 | 06 Mar 2026 |
| Potts JeannetteChief Legal Officer | Sale | 3,412 | $9.06 | $30.91K | 04 Mar 2026 | 06 Mar 2026 |
| Abi-Saab WalidChief Medical Officer | Sale | 808 | $9.06 | $7.32K | 04 Mar 2026 | 06 Mar 2026 |
| KLEMT CHRISTIANChief Financial Officer | Sale | 12,000 | $9.06 | $108.72K | 04 Mar 2026 | 06 Mar 2026 |
| Jeannette PottsChief Legal Officer | Sale | 3,412 | $9.06 | $30.91K | 04 Mar 2026 | 06 Mar 2026 |
| Christian KlemtChief Financial Officer | Sale | 12,000 | $9.06 | $108.72K | 04 Mar 2026 | 06 Mar 2026 |
| Matthew C KapustaCEO, Managing Director | Sale | 14,581 | $9.06 | $132.10K | 04 Mar 2026 | 06 Mar 2026 |
| Walid Abi-SaabChief Medical Officer | Sale | 808 | $9.06 | $7.32K | 04 Mar 2026 | 06 Mar 2026 |
| KLEMT CHRISTIANChief Financial Officer | Sale | 12,532 | $9.95 | $124.69K | 02 Mar 2026 | 04 Mar 2026 |
| Potts JeannetteChief Legal Officer | Sale | 8,578 | $9.95 | $85.35K | 02 Mar 2026 | 04 Mar 2026 |
| Kapusta Matthew CCEO, Managing Director | Sale | 34,437 | $9.95 | $342.65K | 02 Mar 2026 | 04 Mar 2026 |
| Abi-Saab WalidChief Medical Officer | Sale | 1,660 | $9.95 | $16.52K | 02 Mar 2026 | 04 Mar 2026 |
| Kapusta Matthew CCEO, Managing Director | Sale | 12,378 | $23.86 | $295.34K | 25 Feb 2026 | 27 Feb 2026 |
| KLEMT CHRISTIANChief Financial Officer | Sale | 6,217 | $23.86 | $148.34K | 25 Feb 2026 | 27 Feb 2026 |
| Gut Robert | Sale | 7,803 | $25.09 | $195.78K | 12 Jan 2026 | 14 Jan 2026 |
| Gut Robert | Sale | 500 | $25.03 | $12.52K | 12 Jan 2026 | 14 Jan 2026 |
| Gut Robert | Sale | 17,310 | $24.39 | $422.19K | 12 Jan 2026 | 14 Jan 2026 |
| Kaye Jack | Sale | 6,390 | $27.28 | $174.32K | 09 Jan 2026 | 12 Jan 2026 |
| Gut Robert | Sale | 15,594 | $27.30 | $425.72K | 06 Nov 2025 | 10 Nov 2025 |
| Gut Robert | Sale | 15,840 | $27.22 | $431.16K | 06 Nov 2025 | 10 Nov 2025 |
| Kaye Jack | Sale | 17,810 | $30.33 | $540.18K | 04 Nov 2025 | 06 Nov 2025 |
| Kaye Jack | Sale | 10,000 | $30.36 | $303.60K | 04 Nov 2025 | 06 Nov 2025 |
| Kaye Jack | Sale | 11,000 | $30.34 | $333.74K | 04 Nov 2025 | 06 Nov 2025 |
| Jack KayeDirector | Sale | 10,000 | $30.36 | $303.60K | 04 Nov 2025 | 06 Nov 2025 |
| Jack KayeDirector | Sale | 17,810 | $30.33 | $540.18K | 04 Nov 2025 | 06 Nov 2025 |
| Jack KayeDirector | Sale | 11,000 | $30.34 | $333.74K | 04 Nov 2025 | 06 Nov 2025 |
Frequently Asked Questions
What is QURE stock price today?
UNIQURE NV (QURE) is currently trading at $17.16. The stock has a 52-week range of $8.34 to $70.59 and a market capitalization of $1.07B.
Is QURE a good stock to buy in 2026?
UNIQURE NV has a P/E ratio of N/A (forward P/E: N/A), a dividend yield of none, and 1-year performance of +76.0%. 1 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling QURE stock?
There have been 26 insider transactions for QURE in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has QURE stock performed over the past year?
UNIQURE NV (QURE) has returned +76.0% over the past 12 months. The stock traded between $8.34 and $70.59 during this period, and is currently at $17.16.
Which hedge funds own QURE (UNIQURE NV)?
1 tracked hedge funds currently hold QURE in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is QURE's market cap and valuation?
UNIQURE NV (QURE) has a market capitalization of $1.07B. The trailing P/E ratio is N/A and forward P/E is N/A. The stock is classified in the Healthcare sector.
What is QURE's revenue and profitability?
UNIQURE NV reported revenue of $16.10M with net income of N/A and a profit margin of N/A. The stock has a beta of 0.75.
What sector is QURE in and who are its biggest institutional holders?
UNIQURE NV (QURE) operates in the Healthcare sector. It is held by 1 tracked hedge funds. See the ownership table above for the complete list.